TAM Receptor

AXL-IN-14 is a highly potent, orally bioavailable inhibitor of AXL, exhibiting an impressive IC50 value of 0.8 nM. This compound effectively disrupts Gas6/AXL-mediated cell migration and invasion while reducing the expression levels of phospho-AXL and phospho-AKT proteins. AXL-IN-14 demonstrates significant anti-tumor activity, making it a valuable tool for research in cancer therapeutics and metastasis studies.

Axl-IN-5 is a selective inhibitor of AXL, exhibiting an IC50 of 283 nM. This compound demonstrates significant anticancer activity, making it a valuable tool for research in cancer biology. Axl-IN-5 can be utilized to study the role of AXL signaling in tumor progression and to investigate potential therapeutic strategies targeting the AXL pathway in various malignancies.

(Z)-S49076 hydrochloride is a potent inhibitor of MET and AXL, effectively disrupting their downstream signaling pathways. This compound demonstrates significant biological activity by inhibiting the proliferation and migration of tumor cells and suppressing tumor growth in xenograft models. Additionally, (Z)-S49076 hydrochloride addresses resistance mechanisms associated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in Erlotinib-resistant cell lines. It is a valuable tool for research in non-small cell lung cancer (NSCLC).

Denfivontinib hydrochloride is an AXL inhibitor that exerts synergistic antitumor effects when used in combination with the PD-1 inhibitor Pembrolizumab. This compound enhances the NOD-like receptor pathway, facilitating the formation of the NLRP3 inflammasome. Its unique mechanism of action makes it a valuable tool for cancer research, particularly in studying immune modulation and tumor progression.

ER-851 is a selective inhibitor of AXL with an IC50 of 100 nM, demonstrating potent oral bioactivity. It has been shown to exhibit antitumor effects, making it a valuable compound for research in cancer biology and therapeutic development. Its selectivity and efficacy position ER-851 as a critical tool for studying AXL's role in tumor progression and metastasis.